Existing methods for engineering conditional mutations in cultured cells [9] [10] [11] [12] rely on the inclusion of a drug selection cassette that must be removed in a second step to ensure proper expression of the targeted conditional allele ( Supplementary  Fig. 1a,b) . These methods were not designed for the generation of conditional loss-of-function models in a single step, particularly where the target gene is essential for cell growth or viability. To overcome these limitations, our strategy combines an invertible intronic cassette (FLIP), which is similar to COIN 12 , with high efficiency Cas9-assisted gene editing. Critically, the nonmutagenic orientation of the FLIP cassette expresses a puromycin resistance gene (puro R ), allowing selection of correct nuclease-assisted targeting into the exon of one allele and simultaneous enrichment of cells that inactivate the second allele by nuclease-mediated NHEJ (Fig. 1a) . Upon exposure to Cre recombinase, the FLIP cassette is inverted to a mutagenic configuration that activates a cryptic splice acceptor and polyadenylation signal (pA) and disrupts the initial splicing acceptor, resulting in the complete loss of gene function ( Fig. 1b and Supplementary Fig. 2a) . In contrast to COIN, which requires the removal of the drug selection cassette, our FLIP cassette permits the generation of conditional mutant cells in one step.
Existing methods for engineering conditional mutations in cultured cells [9] [10] [11] [12] rely on the inclusion of a drug selection cassette that must be removed in a second step to ensure proper expression of the targeted conditional allele ( Supplementary  Fig. 1a,b) . These methods were not designed for the generation of conditional loss-of-function models in a single step, particularly where the target gene is essential for cell growth or viability. To overcome these limitations, our strategy combines an invertible intronic cassette (FLIP), which is similar to COIN 12 , with high efficiency Cas9-assisted gene editing. Critically, the nonmutagenic orientation of the FLIP cassette expresses a puromycin resistance gene (puro R ), allowing selection of correct nuclease-assisted targeting into the exon of one allele and simultaneous enrichment of cells that inactivate the second allele by nuclease-mediated NHEJ (Fig. 1a) . Upon exposure to Cre recombinase, the FLIP cassette is inverted to a mutagenic configuration that activates a cryptic splice acceptor and polyadenylation signal (pA) and disrupts the initial splicing acceptor, resulting in the complete loss of gene function ( Fig. 1b and Supplementary Fig. 2a) . In contrast to COIN, which requires the removal of the drug selection cassette, our FLIP cassette permits the generation of conditional mutant cells in one step.
Initially we inserted a variant of the FLIP cassette containing a DsRed2 reporter in place of puro R into a cytomegalovirus promoter-enhanced green fluorescent protein (CMV-eGFP) expression plasmid (CMV-eGFP [FLIP] , Fig. 1c) . Following transient transfection of HEK293 cells with CMV-eGFP [FLIP] , both green and red fluorescence were observed, demonstrating that the FLIP cassette inserted in the non-mutagenic orientation is inert (Fig. 1d) . This was further confirmed by flow cytometry analysis, showing a similar level of eGFP expression from both CMV-eGFP and CMF-eGFP [FLIP] (Supplementary Fig. 3 ). The Cre-recombined CMV-eGFP [FLIP] showed loss of eGFP expression, suggesting the inactivation of eGFP expression in the inverted, mutagenic orientation of the FLIP cassette (Fig. 1c,d) .
Next, we employed CRISPR-Cas9 in mouse embryonic stem cells (mESCs) to introduce the puro R FLIP cassette into one allele of β-catenin (Ctnnb1) via HDR and to simultaneously induce a frameshift mutation by NHEJ in the second Ctnnb1 allele (Fig. 1a,  Supplementary Fig. 4a ). β-catenin is important for the morphology and efficient self-renewal of mESCs 13, 14 . A donor vector containing the puro R FLIP cassette flanked by ~1-kb homology arms was inserted in exon 5 of Ctnnb1 by co-transfection of mESCs with Cas9 and gRNA expression plasmids. Following selection in puromycin, drug-resistant colonies were genotyped by PCR to confirm correct integration of the FLIP cassette and then assayed for NHEJ events in the second allele by Analyzing gene function is a crucial step in advancing our understanding of normal physiology and disease pathogenesis. In cell-based models, loss-of-function studies require inactivation of both copies of the gene. Gene knockouts in cell lines have been achieved by loss-of-heterozygosity 1 or serial gene targeting approaches 2 . The development of site-specific nucleases has greatly facilitated functional studies in cells because both copies of a gene can be efficiently inactivated in a single step 3 . Recently, the CRISPR-Cas9 gene editing technology [4] [5] [6] [7] has become the tool of choice for gene knockout studies owing to its simplicity and robustness. Cas9 nuclease is an RNA-guided nuclease that is highly efficient in inducing a double-strand break (DSB) at a genomic site of interest. These DSBs can be repaired by error-prone non-homologous end joining (NHEJ) to generate gene-inactivating mutations; or, in the presence of a donor template, the DSBs can be repaired by homology-directed repair (HDR) to generate more precise and complex alleles 8 . While simple constitutive knockouts are useful and informative, it is desirable to engineer conditional loss-of-function models, particularly for genes essential for cell viability or embryonic development. Here, we describe a simplified, one-step method for engineering conditional loss-of-function mutations in diploid cells.
Figs. 2b and 4b,c).
From 64 clones, 14 (21.9%) were correctly targeted, among which 4 carried a frameshift mutation in the second allele (Supplementary Table 1 ). The recovery of Ctnnb1 compound mutant clones (FLIP targeted/NHEJ frameshift; FLIP/-) with wild-type morphology strongly suggests that the insertion of the FLIP cassette does not disrupt the function of β-catenin in the nonmutagenic orientation. Upon expression of Cre recombinase in Ctnnb1 FLIP/-clones, we observed a loss of β-catenin expression in cells (Fig. 2a, Supplementary Fig. 4d ). Moreover, compared to control (Ctnnb1 FLIP/+ ) cells treated with Cre recombinase, the Ctnnb1 FLIP/-cells became scattered and lost their dome-like morphology (Fig. 2b) . In addition, we performed quantitative RT-PCR analysis to determine the splicing efficiency of the FLIP intron in comparison to the neighboring intron 7 of β-catenin. Our data demonstrate highly efficient splicing of the FLIP intron. Thus the FLIP cassette is inert to gene activity in the nonmutagenic orientation ( Supplementary Fig. 5 and Supplementary Table 2) .
We additionally targeted Apc, Esrrb, Nfx1, Sox2, Tcf7l2, Trim13 and Trim37 in mESCs; ARID1A and TP53 in human HEK293 cells; and TP53 in human induced pluripotent stem cells ( Supplementary Figs. 6-9 ). The FLIP intron targeting efficiency ranged from 19.8% to 40.6% in mESCs (Supplementary Table 1 ; note that nontargeted clones are a result of random integration of the puro cassette). Importantly, for all genes, FLIP/− clones were obtained (Supplementary Table 1 , Supplementary Figs. 6-9 ). To induce gene knockout, a Cre-expressing plasmid was transfected to embryonic stem cell (ESC) clones with an average transfection efficiency >95% (Supplementary Fig. 10 ) and conditional inactivation of gene expression was confirmed by protein blot and immunofluorescence for Esrrb, Sox2, Trim13 and Trim37 ( Supplementary Figs. 6d ,h,i and 7m,q).
We further modified our FLIP intronic cassette to generate a reversible conditional allele. The region containing the cryptic splice acceptor and pA is flanked by two flippase recognition target (FRT) sites (Supplementary Fig. 11a , FLIP-Flp Excision (FLIP-FlpE)). When inserted into eGFP, the intronic FLIP-FlpE cassette permits the expression of eGFP, like the original FLIP cassette ( Supplementary Figs. 3 and 11b) . Upon Cre recombination, the FLIP-FlpE cassette turns into the mutagenic orientation, which blocks the eGFP expression. Next, the added FRT sites enable the mutagenic FLIP-FlpE cassette to be excised by Flp recombinase, thus allowing the revival of eGFP expression (Supplementary Fig. 11a,b) . The FLIP-FlpE cassette was inserted in exon 5 of the mouse β-catenin allele. The Ctnnb1 FLIP-FlpE/FLIP-FlpE (FLIP-FlpE homozygote) mutant clone went through a series of recombinations, first by Cre and then by Flp. At each step, the mutant showed wild-type, mutant (after Cre) and again wild-type (after Cre and Flp) morphology, respectively (Supplementary Fig. 11e ). Accordingly, we observed loss and gain of β-catenin expression ( Supplementary  Fig. 11f,g ), suggesting that, with a simple modification, the FLIP intronic cassette can also be used for 'switchable' gene expression.
To extend our application, we inserted the FLIP-FlpE cassette into exon 16 of the mouse Apc allele in intestinal organoids expressing CreERT2 under the villin promoter ( Supplementary  Fig. 12a ). Apc is a component of the destruction complex acting in the Wnt pathway, and its deletion causes hyperactive Wnt signaling and makes organoids adopt a cystic morphology 15 . Apc FLIP-FlpE/-clones ( Supplementary Fig. 12b,c) initially showed budding morphology when cultured in standard ENR (Egf, Noggin, Rspondin) medium. Upon treatment with 4-hydroxytamoxifen (4-OHT) for Cre activation, the organoids adopt a cystic morphology due to the loss of Apc (Supplementary Fig. 12d) . In addition to the application of CRISPR-FLIP to intestinal organoids, FLIP-targeted ESC clones can be used to generate other cell types-for example, mouse embryonic fibroblast (MEF) (Supplementary Fig. 13 ). Our strategy requires the presence of a CRISPR site overlapping with or nearby the insertion site of the FLIP cassette, imposing constraints on the exons than can be targeted. To maximize the potential for a null mutation, the target exon must be common to all transcripts and lie within the first 50% of the protein-coding sequence. Additionally, based on the minimum size of mammalian exons (50 bp) 16 , we set the size of the split exons to be at least 60 bp. Finally, for optimal splicing, we chose insertion points that match the consensus sequence for mammalian splice junctions (minimally MAGR ( A / C AG/Pu)) 17 . Using this set of rules, we used bioinformatics to estimate the number of suitable FLIP insertion sites in the protein-coding genes in the mouse and human genomes. Our bioinformatics analysis revealed 1,171,712 FLIP insertion sites and corresponding single guide RNA (sgRNA) binding sites covering 16,460 genes in the mouse genome and 1,171,787 FLIP insertion sites and corresponding sgRNA binding sites covering 15,177 genes in the human genome (Supplementary Tables 3 and 4) . Although haploinsufficient genes impose a limitation on our strategy, as one allele is already null in FLIP/-clones, the generation of FLIP/FLIP clones provide an option for circumventing this difficulty.
Recently developed methods to achieve higher efficiency of HDR-mediated targeting are likely to further increase the efficiency of our CRISPR -FLIP method 18 . The FLIP targeting vectors require only short homologous arms (<1 kb), which makes the assembly of targeting vectors easy and scalable. The FLIP cassette is invariable and can be generically applied to any gene, including noncoding RNA genes. The CRISPR -FLIP technology is widely applicable to many diploid and aneuploid cell types, including mESCs, fibroblasts, 3D organoids, human induced pluripotent stem cells (hiPSCs) and cell lines (such as 293 cells).
methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. onLine methods DsRed FLIP cassette inserted in the eGFP cDNA. The FLIP cassette inserted in the middle of eGFP and containing a DsRed2 reporter gene was synthesized and ordered from GenScript. The split eGFP cDNA and the FLIP cassette were cloned into the mammalian expression vector pCDNA4TO (Invitrogen) using BamHI (R0136S, NEB) and XhoI (R0146S, NEB) for prerecombined form. The vector was subsequently transformed into Cre-expressing bacteria (A111, Gene bridges) to generate the Crerecombined form. Correct clones were confirmed with restriction digest BamHI (R0136S, NEB) and XhoI (R0146S, NEB) and Sanger sequencing. The FLIP-FlpE cassette was also synthesized and inserted into the same site of the eGFP expression vector.
FLIP cassette containing selection marker genes. The FLIP cassette was PCR amplified and cloned into Pjet1.2 vector (ThermoFisher Scientific, K131). Replacement of DsRed was done through restriction digest excision using EcoRI (R3101S, NEB) and Acc65l (RO599S, NEB), followed by insertion of PCRamplified selection marker genes using Infusion cloning (638909, Clontech). The FLIP cassette including the selection marker gene was then transferred to the vector pUC118 (3318, Clontech) using the restriction enzymes SacI (R0156S, NEB) and PstI (R0140S, NEB) and Mighty cloning (6027, Takara).
Addition of homologous arms to the FLIP cassette-FLIP-targeting vector generation.
Homologous arms around an intron insertion site were amplified by high fidelity Phusion DNA polymerase (M0530S, NEB). After PCR product purification, both homologous arms and FLIP cassette-containing vector were mixed with the type II restriction enzyme SapI and T4 DNA ligase (M0202T, NEB). Then, we performed 25 cycles of the following two-step program: 37 °C for 2 min and 16 °C for 5 min. The reaction mixture was directly used for Escherichia coli transformation. DNA was extracted (27106, Qiagen) and analyzed with restriction digest to identify FLIP donor vectors that were correctly assembled.
Cas9 and gRNA plasmids. Cas9 (41815, Addgene) optimized for human codon and empty gRNA vector (41824, Addgene) were obtained from Addgene.
Cell culture. Human embryonic kidney (HEK) 293 cells.
Human embryonic kidney 293 cells were cultured in media consisting of DMEM, high glucose (11965092, Thermofisher Scientific) supplemented with 10% fetal bovine serum (Thermofisher Scientific), 1× penicillin-streptomycin according to the manufacturer's recommendation (P0781, Sigma). The cells were tested negative for mycoplasma.
Embryonic stem cells (ESCs).
Murine E14 Tg2a embryonic stem (mES) cells were cultured feeder-free on 0.1% gelatin-coated dishes in serum + LIF + 2i (Chiron and PD03) composed of GMEM (G5154, Sigma), 10% fetal bovine serum (Gibco), 1× nonessential amino acids according to the manufacturer's recommendation (11140, Thermofisher Scientific), 1 mM sodium pyruvate (113-24-6, Sigma), 2 mM l-glutamine (25030081, Thermofisher Scientific), 1× penicillin-streptomycin according to the manufacturer's recommendation (P0781, Sigma) and 0.1 mM 2-mercaptoethanol (M7522, Sigma), 20 ng/ml murine LIF (Hyvonen lab, Cambridge), 3 µM CHIR99021 and 1 µM PD0325901 (Stewart lab, Dresden). BOBSC 19 human induced pluripotent stem (hiPS) cells were cultured feeder-free on dishes coated with Synthemax II (3535, Corning) in TeSR-E8 media (05940, Stem Cell Technologies). ESCs were kept in a tissue culture incubator at 37 °C and 5% CO 2 . Cells were split in a 1:10 −1:15 ratio every 3-4 d depending on confluence. All cells were tested negative for mycoplasma.
Intestinal organoid culture. Mouse small intestinal organoids were cultured as previously described 20 .
Cell electroporation. For targeting of mESCs, 1 × 10 6 cells were collected and resuspended in magnesium-and calcium-free phosphate-buffered saline (D8537, Sigma). A total of 50 µg of DNA consisting of the targeting vector, Cas9 and gRNA in a 1:1:1 ratio were added to the cells and then transferred to a 4 mm electroporation cuvette (Bio-Rad). Electroporation was performed using Protein blot. Following transfection, ESCs were cultured for 2-5 d and then lysed in buffer containing complete protease-inhibitor cocktail tablets (11697498001, Roche) and centrifuged at 13,000 rpm for 15 min at 4 °C. Protein concentration was measured with Bradford assay (5000204, Bio-Rad) and equal amounts were loaded on a 10% acrylamide gel and run at 120 V for 1.5-2 h. The proteins were subsequently transferred to an Immobilon-FL PVDF 0.45 µm membrane (IPFL00010, Millipore) at 90 V for 1 h, 15 min. The following primary antibodies and dilutions were used to detect the indicated proteins: Rabbit monoclonal antibody against β-catenin (1:1000, 8480S, Cell Signaling), mouse monoclonal against alpha-Tubulin antibody (1:5000, ab7291, Abcam),
